Samantha Semenkow (Citi) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Samantha Semenkow's stock ratings?

About 43% of Samantha's ratings were profitable over a one-year hold, with an average return of -4.9% per rating, measured by 13Foresight from historical prices.

Q: How is Samantha ranked?

Samantha Semenkow is ranked #2108 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Samantha Semenkow

Citi

Samantha Semenkow

Citi

Wall Street Analyst

★★☆☆☆

#2108

on 13Foresight · ranked by our own returns

43%

Success Rate

-4.9%

Average Return

12 of 28 calls profitable · -13.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 43% of Samantha Semenkow's ratings turned a profit when each position was held for 1 year — averaging -4.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

81 Buy 6 Hold 3 Sell

Samantha's Stock Coverage 27 ratings · 2026-06-19

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
SABS SAB Biotherapeutics	Jun 15, 2026	BUY	Strong Buy +161.3% avg upside 13 analysts	$11.00 174.98% Upside	·
CGEM Cullinan Management	Jun 10, 2026	BUY	Strong Buy +125.7% avg upside 15 analysts	$33.00 119.61% Upside	+19.8%
ROIV Roivant Sciences	May 21, 2026	BUY	Strong Buy +2.5% avg upside 17 analysts	$42.00 33.62% Upside	+1.0%
NKTR Nektar Therapeutics	May 13, 2026	BUY	Buy +16.6% avg upside 25 analysts	$151.00 147.70% Upside	-19.8%
BEAM Beam Therapeutics	May 13, 2026	BUY	Strong Buy +51.4% avg upside 25 analysts	$68.00 99.23% Upside	-7.7%
ARGX Argenx Se	May 12, 2026	BUY	Strong Buy -15.9% avg upside 46 analysts	$1152.00 31.26% Upside	+8.6%
CPRX Catalyst Pharma	May 07, 2026	HOLD	Strong Buy -17.0% avg upside 15 analysts	$31.50 0.38% Upside	+0.7%
SYRE Spyre Therapeutics	May 06, 2026	BUY	Strong Buy -15.4% avg upside 23 analysts	$97.00 9.84% Upside	+14.5%
WVE Wave Life Sciences	May 01, 2026	BUY	Strong Buy +261.8% avg upside 28 analysts	$24.00 289.54% Upside	-20.6%
ALLO Allogene Therapeutics	Apr 09, 2026	BUY	Strong Buy +662.8% avg upside 28 analysts	$4.00 99.92% Upside	-34.7%
BHVN Biohaven Ltd.	Apr 02, 2026	BUY	Strong Buy +87.5% avg upside 25 analysts	$17.00 25.22% Upside	+38.5%
AGIO Agios Pharma	Mar 31, 2026	BUY	Strong Buy +73.8% avg upside 29 analysts	$46.00 34.73% Upside	-16.7%
VYGR Voyager Therapeutics	Mar 23, 2026	BUY	Strong Buy +284.7% avg upside 23 analysts	$11.00 195.71% Upside	-9.8%
MLTX MoonLake Immunotherapeutics	Mar 20, 2026	SELL	Strong Buy +51.6% avg upside 20 analysts	$6.00 68.68% Downside	-17.9%
LRMR Larimar Therapeutics	Mar 20, 2026	BUY	Strong Buy +413.5% avg upside 21 analysts	$14.00 284.70% Upside	-24.3%
RYTM Rhythm Pharmaceuticals	Mar 20, 2026	BUY	Strong Buy +25.2% avg upside 19 analysts	$142.00 46.61% Upside	+9.6%
GPCR Structure Therapeutics, Inc. Sponsored ADR	Mar 16, 2026	BUY	Strong Buy +132.5% avg upside 17 analysts	$100.00 124.59% Upside	-35.4%
BIOA BioAge Labs, Inc.	Mar 10, 2026	BUY	Strong Buy +138.3% avg upside 9 analysts	$52.00 150.37% Upside	-15.8%
SANA Sana Biotechnology	Mar 04, 2026	BUY	Strong Buy +216.4% avg upside 14 analysts	$12.00 280.93% Upside	-25.9%
PRME Prime Medicine, Inc.	Nov 11, 2025	HOLD	Strong Buy +210.0% avg upside 16 analysts	$4.25 31.61% Upside	-21.9%
CABA Cabaletta Bio	Oct 10, 2025	BUY	Strong Buy +390.0% avg upside 16 analysts	$10.00 252.05% Upside	+42.7%
IMVT Immunovant	Aug 12, 2025	BUY	Strong Buy +9.0% avg upside 24 analysts	$57.00 61.27% Upside	+128.2%
EDIT Editas Medicine	Mar 06, 2025	BUY	Buy +420.3% avg upside 33 analysts	$5.00 85.84% Upside	+12.4%
FTH Faeth Therapeutics	Jun 03, 2024	BUY	Strong Buy +107.4% avg upside 11 analysts	$4.00 77.60% Downside	·
NMTRQ 9 Meters Biopharma	May 18, 2023	HOLD	Buy +3234374900.0% avg upside 11 analysts	$0.75 74999900.06% Upside	·
ZLAB Zai Lab	May 11, 2023	BUY	Strong Buy +223.0% avg upside 13 analysts	$130.00 615.08% Upside	-45.3%
ARDX Ardelyx	Jul 21, 2021	BUY	Strong Buy +124.7% avg upside 21 analysts	$7.00 15.72% Upside	-62.5%

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Samantha Semenkow — Frequently Asked Questions

How accurate are Samantha Semenkow's stock ratings?

Based on the calls 13Foresight could measure, about 43% of Samantha's ratings were profitable over a one-year hold, with an average return of -4.9% per rating, or -13.3% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Samantha ranked on 13Foresight?

Samantha Semenkow is currently ranked #2108 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Samantha cover?

Samantha most recently has ratings on SABS, CGEM, ROIV, NKTR, BEAM, ARGX, CPRX, SYRE, WVE, ALLO, BHVN, AGIO and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!